6:13 PM
 | 
Oct 09, 2007
 |  BC Extra  |  Clinical News

Alacrity's ALTY-0501 misses dry eye endpoint

Alacrity (Laguna Hills, Calif.) said ALTY-0501 missed the primary endpoint of a significant reduction in central...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >